Viral Hepatitis B and Chemotherapy
| Autor: | I. Elkoti, R. Laroussi, R. Berreda, A. Benhamdane, O. Mohammed, T. Addajou, S. Mrabti, S. Sentissi, F. Rouibaa, A. Benkirane, H. Seddik |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Scholars Journal of Applied Medical Sciences. 10:790-792 |
| ISSN: | 2320-6691 2347-954X |
| Popis: | Patients with chronic hepatitis B treated with chemotherapy or immunotherapy are at risk of viral reactivation, which can have serious or even fatal consequences [1]. Patients treated with chemotherapy for haematological disease have a known risk of hepatitis B virus (HBV) reactivation with an estimated incidence of 14-72% [2]. The majority of chemotherapy drugs can induce HBV reactivation in patients with HBs-positive antigen [3]. HBs testing should therefore be recommended prior to chemotherapy. Preventive antiviral treatment will reduce the risk of HBV reactivation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|